Esteve invests €100 million in new manufacturing plant in Spain
![](/46/pdcnewsitem/12/48/74/784x590%20news%20header%20(69).png)
Esteve team. Source: [1]
Spain-headquartered CMO Esteve expands its manufacutring capacity in plants in Girona, Spain to increase global API offerings with advanced technological solutions, through a weighty investment of €100 million.
Esteve is a leading healthcare company and pharmaceutical innovator and partner based in Spain.
Esteve has a global presence, mostly throughout Europe, but with industrial sites in China and Mexico. In Spain, Esteve has a chemical R&D centre in Barcelona, and three production plants in the Catalan region, located in Celrà (Gironès), Banyeres del Penedès (Baix Penedès), and Lliçà de Vall (Vallès Oriental). Now, they have plans to further increase manufacturing capacity in the region.
Esteve has initiated a project to construct a new manufacturing unit at its Celrà plant in Girona, with plans to invest €100 million through to 2026. The expansion aims to boost the production capacity of active pharmaceutical ingredients at its primary industrial site. Once the new facilities become operational in the latter quarter of 2026, the company will welcome approximately 100 new employees to its existing team of 370 professionals. The expansion includes building new production and service facilities and installing up to 150 m3 of reaction volume, leading to a 45% increase in Esteve's production capacity at Celrà and a 15% increase in the overall global capacity of the company.
The new unit in Girona illustrates the dedication to advancements in developing, manufacturing, and sales of APIs for CMOs. The latest technological solutions, including in digitalisation and data analysis, incorporated into the facility will ensure the efficient production of highly-potent APIs.
The facility enables the production of new products to be added to Esteve’s portfolio, which will be distributed throughout the USA, Europe, and Japan.
"Thanks to our commitment to quality, efficiency and reliability, our activity in the development and manufacturing of active pharmaceutical ingredients has experienced notable growth in recent years. The expansion of our main industrial centre will allow us to satisfy a growing global demand and expand our activity, advancing our mission of improving people's lives", commented Pere Mañé, the General Manager of Esteve Química.
Source:
[1] Esteve Química. Esteve will invest 100 million euros in the construction of a new plant at its industrial centre in Celrà (Girona). [Date accessed 09/07/2024] www.esteve.com/global/news/esteve-will-invest-100-million-euros-in-the-construction-of-a-new-plant-at-its-industrial-centre-in-celra-girona
Related News
-
News How are new PFAS regulations impacting excipient manufacture? – CPHI North America Interview
In another interview from CPHI North America in Philadelphia in May, Peter Schmitt from Montesino Associates talks about his presentation on 'Navigating the Waters of Change: The Impact of New PFAS Regulations on the Manufacture of Excipients ... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Press release: CPHI Sustainability Report 2024 – a guide to a greener industry
The CPHI Pharma portfolio is pleased to announce that their annual Sustainability Report has been published, with thought leaders outlining a guide to a greener pharmaceutical industry. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News Pharma giants battle over COVID-19 patents in London courts
Two key players in the COVID-19 vaccine story – Pfizer/BioNTech and Moderna – have begun the latest chapter of their global legal battle over patents concerning technology for the development of mRNA therapeutics such as the COVID-19 vaccin... -
News Western pharma groups warn of supply disruptions over China anti-spy law
China’s anti-espionage laws have caused concern among western pharmaceutical groups over potential arrests or denial of access for foreign inspectors in China-based facilities and manufacturing partners, posing a risk to the supply of drug produc... -
News The EU Commission proposes updates to EU pharmaceutical legislation
The EU Commission proposes reform to the current EU pharmceutical legislation in regard to the protection of data and the use of generics and biosimilars for drug companies in the EU.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance